Corporate VC Backing Influences Private M&A Step-Ups

New data show that including one or more corporate venture investors in a syndicate actually translates into a higher median step-up valuation.

In the wake of the 2008–2009 financial crisis, there has been a decided uptick in corporate venture activity; as traditional venture investors aim to convince LPs to recommit to their funds, they've shifted to later-stage investing, in the hopes of shortening the time to exit. That's created a window of opportunity for strategic investors, who can tap into more innovative projects now at earlier stages. ( See "Corporate Venture Takes Center Stage," START-UP , May 2009 Also see "Corporate Venture Takes Center Stage " - Scrip, 1 May, 2009. and "In the Midst Of A Shakeout, Biotech VCs Must Embrace New Partners, New Math," START-UP , September 2010 Also see "In the Midst Of A Shakeout, Biotech VCs Must Embrace New Partners, New Math" - Scrip, 1 September, 2010..) Bringing in new corporate venture investors at the B or even C round has likely allowed for more up rounds than would have been possible with traditional venture's retrenchment. But there are other advantages as well. In the past, some traditional venture capital firms may have shied away from co-investing with corporate entities. Conventional wisdom suggested that the involvement of such groups might preclude a syndicate's ability to structure an aggressive bidding war for a portfolio company, resulting in a lower overall return. But an analysis by START-UP shows such logic to be outdated. Far from capping an exit, new data show that including one or more corporate venture investors in a syndicate actually translates into a higher median step-up valuation.

Using Elsevier's Strategic Transactions, START-UP identified 92 private biopharma acquisitions completed since 2006. Device, diagnostics, and services companies were excluded....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal

 

Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By 

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By 

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

More from Business

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.